Gill Capital Partners’s Arcus Biosciences RCUS Stock Holding History

Gill Capital Partners’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50	Closed	-$1.08K	–	718
2026 Q1	$1.08K	Buy	+50	New	+$1.08K	﹤0.01%	594

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Gill Capital Partners's RCUS Position: Q2 2026 in Review

Gill Capital Partners sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 50 shares — an estimated $1.08K sold.

Gill Capital Partners first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $1.08K in Q1 2026. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

Gill Capital Partners reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
Gill Capital Partners sold 50 Arcus Biosciences shares in Q2 2026, an estimated $1.08K.
Gill Capital Partners first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
Gill Capital Partners's Arcus Biosciences position peaked at $1.08K in Q1 2026.
232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.